Syndetics cover image
Image from Syndetics

Genzyme : the Renvela launch decision / Tim Calkins & Lynn Harris.

By: Contributor(s): Material type: TextSeries: Publisher: [London] : SAGE, 2016Description: 1 online resource : illustrations (black and white, and colour)Content type:
  • text
  • still image
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781473970014 (ebook) :
Subject(s): DDC classification:
  • 658.575 23
Online resources: Pharmaceutical company Genzyme has created a new drug, Renvela, which is a phosphate binder designed to be used primarily by patients with kidney failure. Renvela is a slightly different version of Genzyme's highly successful Renagel. Company executives must now decide how best to launch Renvela. Should it replace Renagel? Should it be a premium version of Renagel? Is it worth launching the product at all? This case appears rather simple on the surface, but the questions are challenging to work through.
No physical items for this record

Originally Published in: Calkins, T., & Harris, L. (2009). Genzyme: The Renvela Launch Decision. 5-308-506. Evanston, IL: Kellogg School of Management, Northwestern University.

Pharmaceutical company Genzyme has created a new drug, Renvela, which is a phosphate binder designed to be used primarily by patients with kidney failure. Renvela is a slightly different version of Genzyme's highly successful Renagel. Company executives must now decide how best to launch Renvela. Should it replace Renagel? Should it be a premium version of Renagel? Is it worth launching the product at all? This case appears rather simple on the surface, but the questions are challenging to work through.

Description based on online resource; title from home page (viewed on April 28, 2016).

Licensed e-book